5:45 PM
 | 
Jun 24, 2013
 |  BC Extra  |  Clinical News

Sandoz starts Phase III testing of etanercept biosimilar

Sandoz started an international Phase III trial to evaluate a biosimilar of autoimmune drug Enbrel etanercept to treat moderate to severe chronic plaque-type psoriasis. The generics unit of Novartis AG (NYSE:NVS; SIX:NOVN) said data from the trial are expected to support regulatory applications for the biosimilar in the U.S....

Read the full 234 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >